Calliditas Therapeutics AB (CALT) Financial Statements
Calliditas Therapeutics AB (CALT) files with the U.S. Securities and Exchange Commission under CIK 0001795579. 10KGenie shows its annual statements from SEC filings.
Key Figures, Fiscal Year 2023
- Revenue
- 1.21 billion SEK
- Net Income
- -466.19 million SEK
- Total Assets
- 1.86 billion SEK
- Net Cash from Operations
- -434.65 million SEK
Fiscal year ended Dec 31, 2023. Latest periodic SEC filing: Apr 24, 2024. Source: SEC filings (EDGAR XBRL). Amounts in SEK.
Open the full financial statements for CALT in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History